Format

Send to

Choose Destination
Pharmacol Res Perspect. 2015 Jun;3(3):e00138. doi: 10.1002/prp2.138. Epub 2015 May 4.

Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917.

Author information

1
Discovery Science and Technology Department, Daiichi Sankyo RD Novare Co., Ltd. Tokyo, Japan.
2
Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd. Tokyo, Japan.
3
Biologics Technology Research Laboratories, Daiichi Sankyo Co., Ltd. Tokyo, Japan.
4
New Modality Research Laboratories, Daiichi Sankyo Co., Ltd. Tokyo, Japan.

Abstract

CS-917 (MB06322) is a selective small compound inhibitor of fructose 1,6-bisphosphatase (FBPase), which is expected to be a novel drug for the treatment of type 2 diabetes by inhibiting gluconeogenesis. CS-917 is a bisamidate prodrug and activation of CS-917 requires a two-step enzyme catalyzed reaction. The first-step enzyme, esterase, catalyzes the conversion of CS-917 into the intermediate form (R-134450) and the second-step enzyme, phosphoramidase, catalyzes the conversion of R-134450 into the active form (R-125338). In this study, we biochemically purified the CS-917 esterase activity in monkey small intestine and liver. We identified cathepsin A (CTSA) and elastase 3B (ELA3B) as CS-917 esterases in the small intestine by mass spectrometry, whereas we found CTSA and carboxylesterase 1 (CES1) in monkey liver. We also purified R-134450 phosphoramidase activity in monkey liver and identified sphingomyelin phosphodiesterase, acid-like 3A (SMPADL3A), as an R-134450 phosphoramidase, which has not been reported to have any enzyme activity. Recombinant human CTSA, ELA3B, and CES1 showed CS-917 esterase activity and recombinant human SMPDL3A showed R-134450 phosphoramidase activity, which confirmed the identification of those enzymes. Identification of metabolic enzymes responsible for the activation process is the requisite first step to understanding the activation process, pharmacodynamics and pharmacokinetics of CS-917 at the molecular level. This is the first identification of a phosphoramidase other than histidine triad nucleotide-binding protein (HINT) family enzymes and SMPDL3A might generally contribute to activation of the other bisamidate prodrugs.

KEYWORDS:

Biochemical purification; CS-917; FBPase inhibitor; bisamidate prodrug; drug metabolizing enzyme; phosphoramidase

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center